Perceptive Advisors led a $55m round for Ionis-backed rare disease drug developer Dynacure following a 2018 round that was the same size.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Corporate venturing unit Amgen Ventures contributed to a $25.5m funding round for the microfluidics healthcare technology developer.

Cowen and European Investment Bank added $52m to a $130m first tranche closed by the AbbVie and Pfizer-backed kidney injury drug developer in July.

The WuXi-backed investment firm returned for a series B2 round that will support phase 1/2 trials for iTeos Therapeutics' oncology therapies.

Autoimmune disease drug developer Pandion Therapeutics closed a series B round co-led by Access Biotechnology and backed by Roche Venture Fund and SR One.

The Parkinson's disease therapy developer closed the series A funding less than four months after a Eurofarma-backed seed round.

Intel Capital led a $14.1m round for the cancer diagnostics system provider, its parent company having already supplied it with artificial intelligence technology.

Based on research at Grousbeck Gene Therapy Center and Massachusetts Eye and Ear, Affinia has raised $60m in a series A round to advance its gene therapies into the clinic.

Lonza participated in the gene therapy developer's series A round alongside Partners Innovation Fund, having also licensed technology to the startup.